AGO2, argonaute RISC catalytic component 2, 27161

N. diseases: 186; N. variants: 11
Source: ALL
Variant Gene Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs11783023
rs11783023
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C0020676
Disease:
Hypothyroidism 		0.700 GeneticVariation GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
dbSNP: rs2977479
rs2977479
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C0005890
Disease:
Body Height 		0.700 GeneticVariation GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
dbSNP: rs6578125
rs6578125
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C1261502
Disease:
Finding of Mean Corpuscular Hemoglobin 		0.700 GeneticVariation GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
dbSNP: rs2944772
rs2944772
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C0596887
Disease:
mathematical ability 		C 0.700 GeneticVariation GWASCAT Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. 30038396 2018
dbSNP: rs2977464
rs2977464
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C0596887
Disease:
mathematical ability 		T 0.700 GeneticVariation GWASCAT Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. 30038396 2018
dbSNP: rs11166985
rs11166985
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C0018213
Disease:
Graves Disease 		0.010 GeneticVariation BEFREE We genotyped AGO1 rs636832A/G, AGO2 rs7005286C/T, AGO2 rs11166985A/G and AGO2 rs2292779C/G polymorphisms in 184 Graves' disease (GD) patients, 195 Hashimoto's disease (HD) patients and 122 healthy volunteers using the polymerase chain reaction-restriction fragment length polymorphism method. 29256262 2018
dbSNP: rs11166985
rs11166985
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C0018213
Disease:
Graves Disease 		0.010 GeneticVariation BEFREE The G allele of AGO1 rs636832 and the A allele of AGO2 rs11166985 polymorphisms were significantly more frequent in GD patients than in healthy controls. 29256262 2018
dbSNP: rs2292779
rs2292779
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C0018213
Disease:
Graves Disease 		0.010 GeneticVariation BEFREE The AGO2 rs2292779 C carrier and C allele were associated with the intractability of GD. 29256262 2018
dbSNP: rs2292779
rs2292779
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C0018213
Disease:
Graves Disease 		0.010 GeneticVariation BEFREE We genotyped AGO1 rs636832A/G, AGO2 rs7005286C/T, AGO2 rs11166985A/G and AGO2 rs2292779C/G polymorphisms in 184 Graves' disease (GD) patients, 195 Hashimoto's disease (HD) patients and 122 healthy volunteers using the polymerase chain reaction-restriction fragment length polymorphism method. 29256262 2018
dbSNP: rs2292779
rs2292779
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C0020179
Disease:
Huntington Disease 		0.010 GeneticVariation BEFREE We genotyped AGO1 rs636832A/G, AGO2 rs7005286C/T, AGO2 rs11166985A/G and AGO2 rs2292779C/G polymorphisms in 184 Graves' disease (GD) patients, 195 Hashimoto's disease (HD) patients and 122 healthy volunteers using the polymerase chain reaction-restriction fragment length polymorphism method. 29256262 2018
dbSNP: rs2292779
rs2292779
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C0019829
Disease:
Hodgkin Disease 		0.010 GeneticVariation BEFREE We genotyped AGO1 rs636832A/G, AGO2 rs7005286C/T, AGO2 rs11166985A/G and AGO2 rs2292779C/G polymorphisms in 184 Graves' disease (GD) patients, 195 Hashimoto's disease (HD) patients and 122 healthy volunteers using the polymerase chain reaction-restriction fragment length polymorphism method. 29256262 2018
dbSNP: rs2292779
rs2292779
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C0677607
Disease:
Hashimoto Disease 		0.010 GeneticVariation BEFREE We genotyped AGO1 rs636832A/G, AGO2 rs7005286C/T, AGO2 rs11166985A/G and AGO2 rs2292779C/G polymorphisms in 184 Graves' disease (GD) patients, 195 Hashimoto's disease (HD) patients and 122 healthy volunteers using the polymerase chain reaction-restriction fragment length polymorphism method. 29256262 2018
dbSNP: rs4961280
rs4961280
Entrez Id: 27161;104355217
Gene Symbol: AGO2;ERICD
AGO2;ERICD
CUI: C0376358
Disease:
Malignant neoplasm of prostate 		0.010 GeneticVariation BEFREE According to our data, rs3742330, rs4961280 and rs7813 qualify for potentially protective genetic variants against PCa progression. 27498138 2017
dbSNP: rs4961280
rs4961280
Entrez Id: 27161;104355217
Gene Symbol: AGO2;ERICD
AGO2;ERICD
CUI: C0600139
Disease:
Prostate carcinoma 		0.010 GeneticVariation BEFREE According to our data, rs3742330, rs4961280 and rs7813 qualify for potentially protective genetic variants against PCa progression. 27498138 2017
dbSNP: rs3928672
rs3928672
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C2931822
Disease:
Nasopharyngeal carcinoma 		0.010 GeneticVariation BEFREE Moreover, the AGO2 protein expression levels of rs3928672 GA + AA genotype carriers were higher than the GG genotype carriers in the NPC tissues (P = 0.041), and AGO2 was significantly over-expressed in NPC tissues compared with non-cancerous nasopharyngeal tissues (P = 0.011). 26545861 2015
dbSNP: rs4961280
rs4961280
Entrez Id: 27161;104355217
Gene Symbol: AGO2;ERICD
AGO2;ERICD
CUI: C0001973
Disease:
Alcoholic Intoxication, Chronic 		0.010 GeneticVariation BEFREE We found that AGO1 rs595961 (χ(2) = 9.066, p = 0.003; odds ratio [OR] = 0.459, 95% confidence interval [CI]: 0.275-0.768) and AGO2 rs4961280 (χ(2) = 4.111, p = 0.043; OR = 0.590, 95% CI: 0.353-0.986) G alleles have significantly altered the risk for AD, and also there is a significant association of GEMIN4 rs910924 (χ(2) = 5.291, p = 0.021; OR = 1.913, 95% CI: 1.094-3.344) T allele with the risk for AD. 25495208 2015
dbSNP: rs7005286
rs7005286
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C0751690
Disease:
Malignant Peripheral Nerve Sheath Tumor 		0.010 GeneticVariation BEFREE Four SNPs (DDX5 rs1991401, OR=1.79, 95% CI, 1.34-2.38, P=7.90 × 10(-5); DROSHA rs10719, OR=1.64, 95% CI, 1.23-2.20, P=8.76 × 10(-4); AGO2 rs7005286, OR=0.48, 95% CI, 0.32-0.72, P=3.46 × 10(-4); GEMIN4 rs7813, OR=0.50, 95% CI, 0.34-0.72, P=2.65 × 10(-4)) were significantly associated with MPNST risk. 23763827 2013
dbSNP: rs3864659
rs3864659
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C0678222
Disease:
Breast Carcinoma 		0.010 GeneticVariation BEFREE In all women, 3 SNPs (AGO1 rs595055, AGO2 rs3864659, and p68 rs1991401) were significantly associated with breast cancer risk. 21766210 2011
dbSNP: rs3864659
rs3864659
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C0006142
Disease:
Malignant neoplasm of breast 		0.010 GeneticVariation BEFREE In all women, 3 SNPs (AGO1 rs595055, AGO2 rs3864659, and p68 rs1991401) were significantly associated with breast cancer risk. 21766210 2011
dbSNP: rs3864659
rs3864659
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C0006826
Disease:
Malignant Neoplasms 		0.010 GeneticVariation BEFREE The protective effects of AGO2 rs3864659 and HIWI rs11060845 were more pronounced in progesterone receptor-positive (PR+) cancer than in progesterone receptor-negative (PR-) cancer (odds ratio (OR), 0.50; 95% confidence interval (CI), 0.30-0.84 vs. OR, 0.94; 95% CI, 0.60-1.84; P (heterogeneity) = 0.04 and OR, 0.57; 95% CI, 0.37-0.88 vs. OR, 0.97; 95% CI, 0.65-1.44; P (heterogeneity) = 0.02, respectively), and the DROSHA rs644236 had stronger association with estrogen receptor-negative (ER-) cancer than for estrogen receptor-positive (ER+) cancer (OR, 1.39; 95% CI, 1.08-1.78 vs. OR, 1.05; 95% CI, 0.85-1.29; P (heterogeneity) = 0.04). 21766210 2011
dbSNP: rs3864659
rs3864659
Entrez Id: 27161
Gene Symbol: AGO2
AGO2
CUI: C1306459
Disease:
Primary malignant neoplasm 		0.010 GeneticVariation BEFREE The protective effects of AGO2 rs3864659 and HIWI rs11060845 were more pronounced in progesterone receptor-positive (PR+) cancer than in progesterone receptor-negative (PR-) cancer (odds ratio (OR), 0.50; 95% confidence interval (CI), 0.30-0.84 vs. OR, 0.94; 95% CI, 0.60-1.84; P (heterogeneity) = 0.04 and OR, 0.57; 95% CI, 0.37-0.88 vs. OR, 0.97; 95% CI, 0.65-1.44; P (heterogeneity) = 0.02, respectively), and the DROSHA rs644236 had stronger association with estrogen receptor-negative (ER-) cancer than for estrogen receptor-positive (ER+) cancer (OR, 1.39; 95% CI, 1.08-1.78 vs. OR, 1.05; 95% CI, 0.85-1.29; P (heterogeneity) = 0.04). 21766210 2011